Atlas Trials

Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma

Clinical trial NCT02115243 · COMPLETED

Trial details

NCT number
NCT02115243
Sponsor
Duke University
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Unresectable Melanoma
Start date
2014-05-01
Primary completion
2015-12-07
Enrollment
4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.